Literature DB >> 8740140

Potencies of antagonists chemically related to iodoproxyfan at histamine H3 receptors in mouse brain cortex and guinea-pig ileum: evidence for H3 receptor heterogeneity?

E Schlicker1, M Kathmann, H Bitschnau, I Marr, S Reidemeister, H Stark, W Schunack.   

Abstract

We determined the affinities of 16 newly synthesized H3 receptor antagonists in an H3 receptor binding assay and the potencies of 12 of these compounds at functional H3 receptors in the mouse brain cortex and guinea-pig ileum. The compounds differ from histamine in that the C-C-N side chain is replaced by a chain of the structure C-C-C-O. The two major aims of the study were (1) to investigate whether the two functional H3 receptors are pharmacologically different and (2) to derive structure-activity relationships. The specific binding of 3H-Na-methylhistamine to rat brain cortex membranes was monophasically displaced by each of the 16 compounds at pKi values ranging from 7.30 to 9.48. In superfused mouse brain cortex slices preincubated with 3H-noradrenaline, the electrically evoked tritium overflow was slightly decreased by iodoproxyfan and its deiodo analogue; this effect was counteracted by the H3 receptor antagonist clobenpropit. The other compounds did not affect the evoked tritium overflow by themselves. The concentration-response curve of histamine for its inhibitory effect on the electrically evoked tritium overflow was shifted to the right by the 12 compounds with apparent pA2 values ranging from 7.02 to 9.00. The 12 compounds also shifted to the right the concentration-response curve of R-a-methylhistamine for its inhibitory effect on the electrically induced contraction in guinea-pig ileum strips; the apparent pA2 values ranged from 5.97 to 9.00. Iodoproxyfan decreased the electrically induced contraction by itself and this effect was counteracted by the H3 receptor antagonist thioperamide. The apparent pA2 values in the two functional H3 receptor models showed a highly significant correlation (r = 0.882; P < 0.001). Highly significant correlations were also obtained when the pKi values of the compounds in the binding assay were compared to their apparent pA2 values in the mouse brain (r = 0.799; P < 0.004) and in the guinea-pig ileum (r = 0.851; P < 0.001). In each of the three experimental models, iodoproxyfan was the most potent compound; its deiodo analogue was less potent by more than 1.1 log units. The present results show that the compounds under study possess moderate to high affinity and/or (partial) H3 receptor antagonist potency. The two functional H3 receptors in the mouse brain cortex and the guinea-pig ileum may be slightly different; further studies are necessary to clarify whether this difference is due to H3 receptor heterogeneity, species variants or differences in the efficiency of receptor coupling. The marked difference in the affinity/potency between iodoproxyfan and its deiodo analogue may suggest that a highly lipophilic residue in that part of the molecule favours a high affinity/antagonistic potency at H3 receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740140     DOI: 10.1007/bf00169166

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  A simple and rapid in vitro test system for the screening of histamine H3 ligands.

Authors:  R C Vollinga; O P Zuiderveld; H Scheerens; A Bast; H Timmerman
Journal:  Methods Find Exp Clin Pharmacol       Date:  1992-12

Review 2.  Histaminergic transmission in the mammalian brain.

Authors:  J C Schwartz; J M Arrang; M Garbarg; H Pollard; M Ruat
Journal:  Physiol Rev       Date:  1991-01       Impact factor: 37.312

3.  Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program.

Authors:  G A McPherson; P Molenaar; C Raper; E Malta
Journal:  J Pharmacol Methods       Date:  1983-12

4.  Effects of iodoproxyfan, a potent and selective histamine H3 receptor antagonist, on alpha 2 and 5-HT3 receptors.

Authors:  E Schlicker; H Pertz; H Bitschnau; K Purand; M Kathmann; S Elz; W Schunack
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

5.  [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.

Authors:  X Ligneau; M Garbarg; M L Vizuete; J Diaz; K Purand; H Stark; W Schunack; J C Schwartz
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

6.  Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum.

Authors:  S J Taylor; G J Kilpatrick
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  Histamine H3A receptor-mediated inhibition of noradrenaline release in the mouse brain cortex.

Authors:  E Schlicker; A Behling; G Lümmen; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

8.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.

Authors:  J M Arrang; M Garbarg; J C Schwartz
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

9.  Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain.

Authors:  F P Jansen; T S Wu; H P Voss; H W Steinbusch; R C Vollinga; B Rademaker; A Bast; H Timmerman
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Nordimaprit, homodimaprit, clobenpropit and imetit: affinities for H3 binding sites and potencies in a functional H3 receptor model.

Authors:  M Kathmann; E Schlicker; M Detzner; H Timmerman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

View more
  6 in total

1.  Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Authors:  David G Witte; Betty Bei Yao; Thomas R Miller; Tracy L Carr; Steven Cassar; Rahul Sharma; Ramin Faghih; Bruce W Surber; Timothy A Esbenshade; Arthur A Hancock; Kathleen M Krueger
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

2.  Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.

Authors:  T Nickel; U Bauer; E Schlicker; M Kathmann; M Göthert; A Sasse; H Stark; W Schunack
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Correlation of apparent affinity values from H3-receptor binding assays with apparent affinity (pKapp) and intrinsic activity (alpha) from functional bioassays.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

5.  Evidence that histamine homologues discriminate between H3-receptors in guinea-pig cerebral cortex and ileum longitudinal muscle myenteric plexus.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  Identification and characterization of ZEL-H16 as a novel agonist of the histamine H3 receptor.

Authors:  Ying Shi; Rong Sheng; Tingting Zhong; Yu Xu; Xiaopan Chen; Dong Yang; Yi Sun; Fenyan Yang; Yongzhou Hu; Naiming Zhou
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.